Richard Rudick, MD

  • VP Development Sciences, Biogen

Dr. Rudick graduated from Case Western Reserve University School of Medicine in 1975. Following internship and residency in Medicine at the University of Connecticut, Dr. Rudick trained in Neurology at the University of Rochester. During a post-doctoral research fellowship and early career development at the University of Rochester, his studies focused on neurologic consequences of immune disease in animals and immunologic abnormalities in multiple sclerosis(MS) patients. In 1987, Dr. Rudick became Director of the Mellen Center forMultiple Sclerosis at Cleveland Clinic. Driven by a vision of compassionate multidisciplinary MS care integrated with clinical and translational research, the Mellen Center developed an international reputation for excellence in MS treatment, search, and education. Dr. Rudick’s research has focused on experimental therapeutics, including innovative approaches to measuring immunologic, clinical, and imaging features of the disease for use in clinical research and practice. He played key roles in development of IFNß-1a (Avonex) and natalizumab (Tysabri) for relapsing forms of MS. For 30 years, his clinical practice focused on diagnosis and management of MS patients. In addition to directing the Mellen Center, Dr. Rudick was the Chief Clinical Research Officer at Cleveland Clinic from 2001 – 2007, Vice Chairman for Research and Development in the Neurological Institute at Cleveland Clinic from 2007 – 2014, and Co-Principal Investigator of the city wide NIH Clinical and Translational Science Collaborative (CTSA) from 2006 – 2014. In 2014, Dr. Rudick transitioned to Biogen, where he is Vice President, Development Science, and Director of the Value Based Medicine MS Innovation Hub. The VBM iHub is charged with enhancing MS care through technology, innovation, and continuous learning.

This speaker appears at this event: